BCRX Quote, Financials, Valuation and Earnings

Bruker Corp. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -6.8%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Bruker Corp.'s return on equity of -1.2%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.50, signalling upside risk potential of 203.7%. On the other hand Bruker Corp. has an analysts' consensus of $54.07 which suggests that it could grow by 3.76%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Bruker Corp., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Bruker Corp..

BioCryst Pharmaceuticals, Inc. has a beta of 0.804, which suggesting that the stock is 19.61% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.854%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.38% to investors and pays a quarterly dividend of $0.05 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Bruker Corp.'s net income of -$58.5M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.44x versus 2.30x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Hologic, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of 17.85%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Hologic, Inc.'s return on equity of 11.59%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.50, signalling upside risk potential of 203.7%. On the other hand Hologic, Inc. has an analysts' consensus of $76.92 which suggests that it could grow by 2.41%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Hologic, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Hologic, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.804, which suggesting that the stock is 19.61% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.493%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are smaller than Hologic, Inc. quarterly revenues of $1B. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is lower than Hologic, Inc.'s net income of $187.3M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Hologic, Inc.'s PE ratio is 30.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.44x versus 4.16x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

KalVista Pharmaceuticals, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -361.39%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.50, signalling upside risk potential of 203.7%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $33.22 which suggests that it could grow by 100.86%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than KalVista Pharmaceuticals, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.804, which suggesting that the stock is 19.61% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.144, suggesting its less volatile than the S&P 500 by 114.385%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.44x versus 57.38x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viatris, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -3.41%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Viatris, Inc.'s return on equity of -21.75%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.50, signalling upside risk potential of 203.7%. On the other hand Viatris, Inc. has an analysts' consensus of $12.7778 which suggests that it could fall by -3.49%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Viatris, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Viatris, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.804, which suggesting that the stock is 19.61% less volatile than S&P 500. In comparison Viatris, Inc. has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.679%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris, Inc. offers a yield of 3.63% to investors and pays a quarterly dividend of $0.12 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viatris, Inc. pays out 90.63% of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are smaller than Viatris, Inc. quarterly revenues of $3.8B. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Viatris, Inc.'s net income of -$128.2M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viatris, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.44x versus 1.11x for Viatris, Inc.. Usually stocks with elevated PS ratios are considered overvalued.